ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed $200 M

Proceeds to Further Advance Company’s Lead Clinical ProgramsSAN DIEGO--(BUSINESS WIRE)--ADARx Pharmaceuticals, Inc. (“ADARx” or “the Company”), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the successful close of an oversubscribed $200 million Series C financing...

Related Keywords

San Diego ,California ,United States ,Blackrock ,Chen Yu ,Zhen Li ,Ricky Sun ,Marshall Wace ,Adarx Pharmaceuticals ,Company Lead Clinical Programs ,Redmile Group ,Partner At Bain Capital Life Sciences ,T Rowe Price Associates Inc ,Bain Capital Life Sciences ,Adarx Pharmaceuticals Inc ,Further Advance Company ,Lead Clinical ,Commodore Capital ,Cormorant Asset Management ,Price Associates Inc ,Venrock Healthcare Capital Partners ,Ascenta Capital ,Lilly Asia Ventures ,Capital Management ,Chief Executive Officer ,Bain Capital Life ,Managing Partner ,